. Author manuscript; available in PMC: 2014 Sep 7.

Published in final edited form as: Nat Genet. 2010 Jul 11;42(8):692–697. doi: 10.1038/ng.622

Table 3. Association of rs7025486[A] with venous thromboembolism and pulmonary embolism.

Sample set	n_c^a	n_a^a	rs7025486[A]				P_het^c

			f_c^b	f_a^b	OR (95% CI)	P
Venous thromboembolism
Iceland^d	5,863	1,019	0.298	0.321	1.14 (1.03–1.25)	0.011
Canada 1	226	187	0.257	0.246	0.95 (0.68–1.30)	0.73
Canada 2	78	27	0.263	0.278	1.08 (0.54–2.16)	0.83
Spain	888	675	0.177	0.196	1.13 (0.94–1.36)	0.18
Combined	7,055	1,908			1.12 (1.07–1.22)	0.0079	0.71
Pulmonary embolism
Iceland^e	5,863	479	0.298	0.336	1.21 (1.07–1.37)	0.0026
Canada
ACE	226	72	0.257	0.271	1.08 (0.70–1.65)	0.74
PEDS	78	26	0.263	0.288	1.14 (0.56–2.29)	0.72
Spain	888	234	0.176	0.218	1.30 (1.01–1.67)	0.045
Combined	7,055	811			1.20 (1.09–1.32)	0.00030	0.97

Association of rs7025486[A] with VTE and pulmonary embolism in several sample sets of European descent

The number of controls n_c and affected individuals n_a

Frequency in controls f_c and in affected individuals f_a

P value for the test of heterogeneity in the effect estimates.

^d,e

We included 1,626 ungenotyped Icelanders with VTE and 901 ungenotyped Icelanders with pulmonary embolism in the analysis, with n_a,eff = 1,554 and 775, respectively, and adjusted the P values for relatedness of the Icelandic individuals by dividing the χ² statistic by the corresponding genomic-control factors λ_g = 1.319 and 1.207.